Trials / Recruiting
RecruitingNCT06102785
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
Phase II Clinical Study of Fruquintinib Combined TAS102 for Second-line Treatment of Advanced Gastric Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer.
Detailed description
A prospective study of Fruquintinib combined with TAS-102 for the posterior line treatment of advanced colorectal cancer is ongoing (NCT05004831). Both Fuquinitinib and TAS-102 are oral drugs, which are convenient to use and avoid the burden of frequent hospitalization. Whether this combination has considerable efficacy in gastric cancer is not clear.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib, TAS102 | Fruquintinib combined with TAS102 |
Timeline
- Start date
- 2023-11-10
- Primary completion
- 2026-10-10
- Completion
- 2026-10-10
- First posted
- 2023-10-26
- Last updated
- 2023-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06102785. Inclusion in this directory is not an endorsement.